Contrasting Krystal Biotech (NASDAQ:KRYS) and Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology (NASDAQ:CRDFGet Rating) and Krystal Biotech (NASDAQ:KRYSGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Volatility and Risk

Cardiff Oncology has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cardiff Oncology and Krystal Biotech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardiff Oncology $360,000.00 161.21 -$28.29 million ($0.71) -1.89
Krystal Biotech N/A N/A -$69.57 million ($3.12) -19.43

Cardiff Oncology has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cardiff Oncology and Krystal Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiff Oncology -7,880.50% -21.05% -20.06%
Krystal Biotech N/A -15.03% -14.17%

Institutional and Insider Ownership

59.5% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 77.9% of Krystal Biotech shares are owned by institutional investors. 4.6% of Cardiff Oncology shares are owned by insiders. Comparatively, 17.8% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cardiff Oncology and Krystal Biotech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology 0 0 4 0 3.00
Krystal Biotech 0 0 6 0 3.00

Cardiff Oncology currently has a consensus target price of $19.33, indicating a potential upside of 1,342.79%. Krystal Biotech has a consensus target price of $101.60, indicating a potential upside of 67.63%. Given Cardiff Oncology’s higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Krystal Biotech.

About Cardiff Oncology (Get Rating)

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

About Krystal Biotech (Get Rating)

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.